ACT Brief: Real-World Data Access Expansion, eSource Implementation at Scale, and FDA Regulatory Setback for Oncolytic Therapy

Applied Clinical Trials · Apr 14, 2026 · 1m

In today's ACT Brief, we examine Thermo Fisher's expanded real-world data access through HealthVerity, how FHIR-based standards are finally enabling scalable eSource implementation, and FDA's second complete response letter for Replimune's oncolytic immunotherapy.